The possibility of rebates attached to Regeneron Pharmaceuticals Inc.'s age-related macular degeneration (AMD) drug Eylea (aflibercept) – such as those offered by the maker of competitor Lucentis – was one of a handful of issues raised by analysts during the company's second quarter earnings call, but CEO Leonard Schleifer declined to tip his hand.